Protocol applies to melanoma of cutaneous surfaces only.

Similar documents
Small Intestine. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition

Pancreas (Exocrine) Protocol applies to all carcinomas of the exocrine pancreas.

Colon and Rectum. Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6th edition

Uterine Cervix. Protocol applies to all invasive carcinomas of the cervix.

Uveal Melanoma. Protocol applies to malignant melanoma of the uvea.

Thyroid Gland. Protocol applies to all malignant tumors of the thyroid gland, except lymphomas.

Procedures Needle Biopsy Transurethral Prostatic Resection Suprapubic or Retropubic Enucleation (Subtotal Prostatectomy) Radical Prostatectomy

Testis. Protocol applies to all malignant germ cell and malignant sex cord-stromal tumors of the testis, exclusive of paratesticular malignancies.

Urinary Bladder, Ureter, and Renal Pelvis

Malignant tumors of melanocytes : Part 3. Deba P Sarma, MD., Omaha

Retinoblastoma. Protocol applies to retinoblastoma only.

Primary Cutaneous Melanoma Pathology Reporting Proforma DD MM YYYY. *Tumour site. *Specimen laterality. *Specimen type

Protocol applies to specimens from patients with Wilms tumor (nephroblastoma) or other renal tumors of childhood.

Non-Hodgkin Lymphoma. Protocol applies to non-hodgkin lymphoma involving any organ system except the gastrointestinal tract.

Melanoma 6/2/2011. Classification and Prognosis. Melanoma Statistics. American Cancer Society

Protocol for the Examination of Specimens From Patients With Merkel Cell Carcinoma of the Skin

Protocol applies to melanoma of cutaneous surfaces only.

Protocol for the Examination of Specimens From Patients With Melanoma of the Skin

Case Scenario 1 Worksheet. Primary Site C44.4 Morphology 8743/3 Laterality 0 Stage/ Prognostic Factors

Update on 8 th Edition Cutaneous AJCC Staging of Primary Cutaneous Melanoma. Michael T. Tetzlaff MD, PhD

Michael T. Tetzlaff MD, PhD

Definition of Synoptic Reporting

47. Melanoma of the Skin

Protocol for the Examination of Specimens From Patients With Melanoma of the Skin

Springer Healthcare. Staging and Diagnosing Cutaneous Melanoma. Concise Reference. Dirk Schadendorf, Corinna Kochs, Elisabeth Livingstone

Cutaneous Melanoma: Epidemiology (USA) The Sentinel Node in Head and Neck Melanoma. Cutaneous Melanoma: Epidemiology (USA)

CAP Cancer Protocol and ecc Summary of Changes for August 2014 Thyroid Agile Release

Protocol for the Examination of Specimens from Patients with Melanoma of the Skin

Protocol for the Examination of Specimens From Patients With Merkel Cell Carcinoma of the Skin

Protocol for the Examination of Specimens From Patients With Squamous Cell Carcinoma of the Skin

Melanoma Update: 8th Edition of AJCC Staging System

STAGE CATEGORY DEFINITIONS

Carcinoma of the Skin

Melanoma Case Scenario 1

46. Merkel Cell Carcinoma

NAACCR Webinar Series 1

Melanoma 10/6/16. Please submit all questions concerning webinar content through the Q&A panel. Reminder:

12. Malignant Melanoma of Skin

Melanoma Case Scenario 1

LOINC. Clinical information. RCPA code. Record if different to report header Operating surgeon name and contact details. Absent.

WHAT DOES THE PATHOLOGY REPORT MEAN?

A PRACTICAL APPROACH TO ATYPICAL MELANOCYTIC LESIONS BIJAN HAGHIGHI M.D, DIRECTOR OF DERMATOPATHOLOGY, ST. JOSEPH HOSPITAL

Protocol for the Examination of Specimens From Patients With Primary Malignant Tumors of the Heart

Michael T. Tetzlaff MD, PhD

David B. Troxel, MD. Common Medicolegal Situations: Misdiagnosis of Melanoma

Epithelial Cancer- NMSC & Melanoma

Melanoma of the Skin INTRODUCTION SUMMARY OF CHANGES

Melanoma of the Skin

Greater Manchester and Cheshire HPB Unit Guidelines for the Assessment & Management of Hepatobiliary and Pancreatic Disease Chapter 14

Precision Surgery for Melanoma

Dermatopathology. Dr. Rafael Botella Estrada. Hospital La Fe de Valencia

Melanoma. Kaushik Mukherjee MD A. Scott Pearson MD

Melanoma Underwriting Presented at 2018 AHOU Conference. Hank George FALU

NAACCR Webinar Series 1

ACRIN 6666 Therapeutic Surgery Form

Protocol applies to adrenal cortical carcinoma. Pheochromocytoma, neuroblastoma, and other adrenal medullary tumors of childhood are excluded.

Descriptor Definition Author s notes TNM descriptors Required only if applicable; select all that apply multiple foci of invasive carcinoma

Polypoid Melanoma, A Virulent Variant of the Nodular Growth Pattern

This protocol is intended to assist pathologists in providing

Surgery for Melanoma and What s on the Horizon

Pathology of the skin. 2nd Department of Pathology, Semmelweis University

Desmoplastic Melanoma R/O BCC. Clinical Information. 74 y.o. man with lesion on left side of neck r/o BCC

NAACCR Hospital Registry Webinar Series

Update on staging colorectal carcinoma, the 8 th edition AJCC. General overview of staging. When is staging required? 11/1/2017

Collaborative Stage for TNM 7 - Revised 12/02/2009 [ Schema ]

Clinical characteristics

Contrast with Australian Guidelines A/Pr Pascale Guitera,

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma

Impact of Prognostic Factors

Toby Maurer, MD University of California, San Francisco. Lifetime risk of an American developing melanoma

Melanoma Quality Reporting

Updates on Melanoma: Are You Following the Latest Guidelines of Care? Jerry Brewer, MD

*OPERATIVE PROCEDURE. Serum tumour markers within normal limits S1.04 PRINCIPAL CLINICIAN

Malignant Melanoma Early Stage. A guide for patients

Kidney Case 1 SURGICAL PATHOLOGY REPORT

An Overview of Melanoma. Harriet Kluger, M.D. Associate Professor Section of Medical Oncology Yale Cancer Center

Seventh Edition Staging 2017 Melanoma. Overview. This webinar is sponsored by. the Centers for Disease Control and Prevention.

Metastatic Melanoma. Cynthia Kwong February 16, 2017 SUNY Downstate Medical Center Department of Surgery Grand Rounds

Subject Index. Dry desquamation, see Skin reactions, radiotherapy

Extrahepatic Bile Ducts

Skin Cancer. 5 Warning Signs. American Osteopathic College of Occupational and Preventive Medicine OMED 2012, San Diego, Monday, October 8, 2012 C-1

Greater Manchester & Cheshire Guidelines for Pathology Reporting for Oesophageal and Gastric Malignancy

The pathology of bladder cancer

Benign versus Cancerous Lesions How to tell the difference FMF 2014 Christie Freeman MD, CCFP, DipPDerm, MSc

Collaborative Stage for TNM 7 - Revised 07/14/2009 [ Schema ]

Epidemiology. Objectives 8/28/2017

Chapter 2 Staging of Breast Cancer

1. Written information to patient /GP: fax ASAP to GP & offer copy of consultation letter.

Malignant Melanoma in Turkey: A Single Institution s Experience on 475 Cases

Protocol for the Examination of Specimens from Patients with Invasive Carcinoma of the Breast

Seventh Edition Staging 2017 Breast

Bone Marrow. Procedures Blood Film Aspirate, Cell Block Trephine Biopsy, Touch Imprint

Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast

Supporting Information

IT S FUNDAMENTAL MY DEAR WATSON! A SHERLOCKIAN APPROACH TO DERMATOLOGY

Dermatopathology: The tumor is composed of keratinocytes which show atypia, increase mitoses and abnormal mitoses.

NUMERATOR: Reports that include the pt category, the pn category and the histologic grade

Patient age and cutaneous malignant melanoma: Elderly patients are likely to have more aggressive histological features and poorer survival

Transcription:

Melanoma of the Skin Protocol applies to melanoma of cutaneous surfaces only. Procedures Biopsy (No Accompanying Checklist) Excision Re-excision Protocol revision date: January 2005 Based on AJCC/UICC TNM, 6 th edition Authors Carolyn Compton, MD, PhD Department of Pathology, McGill University, Montreal, Quebec, Canada Raymond Barnhill, MD Department of Pathology, George Washington University Medical Center, Washington, DC Mark R. Wick, MD Department of Pathology, University of Virginia Health System, Charlottesville, Virginia Charles Balch, MD American Society of Clinical Oncology, Alexandria, Virginia For the Members of the Cancer Committee, College of American Pathologists

Melanoma of the Skin Skin 2005. College of American Pathologists. All rights reserved. The College does not permit reproduction of any substantial portion of these protocols without its written authorization. The College hereby authorizes use of these protocols by physicians and other health care providers in reporting on surgical specimens, in teaching, and in carrying out medical research for nonprofit purposes. This authorization does not extend to reproduction or other use of any substantial portion of these protocols for commercial purposes without the written consent of the College. The College of American Pathologists offers these protocols to assist pathologists in providing clinically useful and relevant information when reporting results of surgical specimen examinations of surgical specimens. The College regards the reporting elements in the Surgical Pathology Cancer Case Summary (Checklist) portion of the protocols as essential elements of the pathology report. However, the manner in which these elements are reported is at the discretion of each specific pathologist, taking into account clinician preferences, institutional policies, and individual practice. The College developed these protocols as an educational tool to assist pathologists in the useful reporting of relevant information. It did not issue the protocols for use in litigation, reimbursement, or other contexts. Nevertheless, the College recognizes that the protocols might be used by hospitals, attorneys, payers, and others. Indeed, effective January 1, 2004, the Commission on Cancer of the American College of Surgeons mandated the use of the checklist elements of the protocols as part of its Cancer Program Standards for Approved Cancer Programs. Therefore, it becomes even more important for pathologists to familiarize themselves with the document. At the same time, the College cautions that use of the protocols other than for their intended educational purpose may involve additional considerations that are beyond the scope of this document. 2

Skin Melanoma of the Skin Summary of Changes to Checklist(s) Protocol revision date: January 2005 No changes have been made to the data elements of the checklist(s) since the January 2004 protocol revision. 3

Melanoma of the Skin Skin Surgical Pathology Cancer Case Summary MELANOMA OF THE SKIN: Excision, Re-Excision Patient name: Surgical pathology number: Note: Check 1 response unless otherwise indicated. Protocol revision date: January 2005 Applies to invasive melanoma only Based on AJCC/UICC TNM, 6 th edition MACROSCOPIC Specimen Type Excision, ellipse Excision, wide Excision, other (specify): Re-excision, ellipse Re-excision, wide Re-excision, other (specify): Lymphadenectomy, sentinel node(s) Lymphadenectomy, regional nodes (specify): Other (specify): Not specified Macroscopic Tumor Present Absent Indeterminate Tumor Site Specify (if known): Not specified Lesion Size Greatest dimension: cm *Additional dimensions: x cm Cannot be determined (see Comment) 4

Skin Melanoma of the Skin Satellite Nodule(s) Absent Present (specify): Cannot be determined *Pigmentation * Present, diffuse * Present, patchy/focal * Indeterminate * Cannot be determined MICROSCOPIC Histologic Type Superficial spreading melanoma Lentigo maligna melanoma Nodular melanoma Acral lentiginous melanoma Mucosal-lentiginous melanoma Desmoplastic (spindle desmoplastic; neuroid) melanoma Neurotropic melanoma Malignant blue nevus Melanoma in congenital melanocytic nevi Minimal deviation (nevoid) melanoma Other (specify): Melanoma, type cannot be determined Ulceration Present Absent Depth of Invasion Specify: mm Cannot be determined (see Comment) 5

Melanoma of the Skin Skin Pathologic Staging (ptnm) Primary Tumor (pt) ptx: Primary tumor cannot be assessed (see Comment) pt0: No evidence of primary tumor ptis: Melanoma in situ (ie, not an invasive tumor: level I) pt1: Melanoma 1.0 mm or less in thickness, with or without ulceration pt1a: Melanoma 1.0 mm or less in thickness and level II or III, no ulceration pt1b: Melanoma 1.0 mm or less in thickness and level IV or V or with ulceration pt2: Melanoma 1.01 to 2mm in thickness, with or without ulceration pt2a: Melanoma 1.01 to 2.0 mm in thickness, no ulceration pt2b: Melanoma 1.01 to 2.0 mm in thickness, with ulceration pt3: Melanoma 2.01 to 4.0 mm in thickness, with or without ulceration pt3a: Melanoma 2.01 to 4.0 mm in thickness, no ulceration pt3b: Melanoma 2.01 to 4.0 mm in thickness, with ulceration pt4: Melanoma greater than 4.0 mm in thickness, with or without ulceration pt4a Melanoma greater than 4.0 mm in thickness, no ulceration pt4b Melanoma greater than 4.0 mm in thickness, with ulceration Regional Lymph Nodes (pn) pnx: Regional lymph nodes cannot be assessed pn0: No regional lymph node metastasis pn1: Metastasis in 1 regional lymph node pn1a: Clinically occult (microscopic) metastasis pn1b: Clinically apparent (macroscopic) metastasis pn2: Metastasis in 2 to 3 regional nodes or intra-lymphatic regional metastasis without nodal metastasis pn2a: Clinically occult (microscopic) metastasis pn2b: Clinically apparent (macroscopic) metastasis pn2c: Satellite or in-transit metastasis without nodal metastasis pn3: Metastasis in 4 or more regional lymph nodes, or matted metastatic nodes, or in-transit metastasis or satellites(s) with metastasis in regional node(s) Number identified: Number containing metastases identified macroscopically: Number containing metastases identified microscopically: Matted nodes: Present Absent Distant Metastasis (pm) pmx: Presence of distant metastasis cannot be assessed pm1: Distant metastasis (documented in this specimen) * pm1a: Metastasis in skin, subcutaneous tissues, or distant lymph nodes * pm1b: Metastasis to lung * pm1c: Metastasis to all other visceral sites or distant metastasis at any site associated with an elevated serum lactic dehydrogenase (LDH) *(Other site, specify: ) 6

Skin Melanoma of the Skin Margins (check all that apply) Lateral Margins Cannot be assessed Uninvolved by invasive melanoma Distance of invasive melanoma from closest lateral margin: mm Involved by invasive melanoma Uninvolved by melanoma in situ Distance of melanoma in situ from closest margin: mm Involved by melanoma in situ Deep Margin Cannot be assessed Uninvolved by invasive melanoma Distance of invasive melanoma from margin: mm Involved by invasive melanoma *Venous (Large Vessel) Invasion (V) * Present * Indeterminate *Perineural Invasion * Present * Indeterminate *Tumor-Infiltrating Lymphocytes * Nonbrisk * Brisk *Tumor Regression * Present involving less than 75% * Present involving 75% or more of lesion 7

Melanoma of the Skin Skin *Mitotic Index * Less than 1 mitotic figure per mm 2 * 1 or more mitotic figure per mm 2 *Additional Pathologic Findings (check all that apply) * Nevus remnant * Actinic keratosis * Other (specify): *Comment(s) 8